| Clinica De Salud Del Valle De Salinas | |
|
24285 Lincoln Street Chualar CA 93925 | |
| (831) 679-0138 | |
| (831) 678-2803 |
| Full Name | Clinica De Salud Del Valle De Salinas |
|---|---|
| Speciality | Clinic/center - Federally Qualified Health Center (fqhc) |
| Location | 24285 Lincoln Street, Chualar, California |
| Authorized Official Name and Position | Maximiliano Cuevas (CEO) |
| Authorized Official Contact | 8317578689 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Clinica De Salud Del Valle De Salinas 440 Airport Blvd Salinas CA 93905-3302 Ph: (831) 679-0138 | Clinica De Salud Del Valle De Salinas 24285 Lincoln Street Chualar CA 93925 Ph: (831) 679-0138 |
| NPI Number | 1033476197 |
|---|---|
| Provider Enumeration Date | 04/13/2012 |
| Last Update Date | 04/13/2012 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033476197 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QF0400X | Clinic/center - Federally Qualified Health Center (fqhc) | 070000277 (California) | Primary |
News Archive
Access to preventive care at no charge to the patient is a tenet of the health law, but differences over just what's considered "preventive" are causing friction between doctors and patients, reports The Wall Street Journal. Other stories look at how California community clinics have yet to see increased demand for primary care doctors and how plans are targeting newly insured diabetics to avoid costly complications.
As 17 year old Daniel Walker was completing his final lap of jogging in his high school gym class on January 19th, he collapsed with a heart attack.
Cell Therapeutics, Inc. announced today that it has been added to the Russell 3000, Russell 2000 and Russell Global Indexes posted by Russell Investments on June 27, 2011.
Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the first data from the dose-escalation portion of the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced solid tumors. The data are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. AG-120 is being developed in collaboration with Celgene.
› Verified 9 days ago